PLIVA Announces Approval for Citalopram Hydrobromide Tablets

Right first time: Pioneering new methods of drug manufacture

Engineers at the University of Leeds have developed a simple technology which can be used in existing chemical reactors to ensure "right first time" drug crystal formation. Ensuring drug crystals are formed correctly is crucial to their efficacy and the efficiency of pharmaceutical manufact ... more

PLIVA to File Lawsuit Against HANFA

PLIVA d.d. announced that it plans to file a lawsuit against the Croatian Financial Services Supervisory Agency (HANFA) with the Administrative Court of the Republic of Croatia, following the notification received on 22 January 2007 of HANFA's Ruling that PLIVA withheld price-sensitive info ... more

PLIVA Announces Changes in Management and Supervisory Boards

Barr Pharmaceuticals, Inc. and its newly acquired subsidiary PLIVA d.d. announced changes to the Management and Supervisory Boards of PLIVA d.d. The changes resulted from the meeting of PLIVA's Supervisory Board that was held on October 30, 2006 in Zagreb, Croatia. Following the successful ... more

PLIVA Announces Approval for Citalopram Hydrobromide Tablets

PLIVA d.d. announced that PLIVA Inc., its US generics subsidiary, has received final approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Citalopram Hydrobromide Tablets 10 mg, 20 mg, and 40 mg. Citalopram Hydrobromide is the AB-r ... more

Forest Laboratories Licenses Novel NMDA Receptor Antagonist from Merz + Co.

Forest Laboratories, Inc. (NYSE: FRX) announced that it has entered into a license agreement for the development and marketing in the United States of neramexane, a patented novel NMDA receptor antagonist developed by Merz + Co. of Germany. Financial terms of the transaction were not disclo ... more